GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Debt-to-Asset

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Debt-to-Asset : 0.08 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Debt-to-Asset?

Freeline Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.29 Mil. Freeline Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.70 Mil. Freeline Therapeutics Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $49.22 Mil. Freeline Therapeutics Holdings's debt to asset for the quarter that ended in Sep. 2023 was 0.08.


Freeline Therapeutics Holdings Debt-to-Asset Historical Data

The historical data trend for Freeline Therapeutics Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Debt-to-Asset Chart

Freeline Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Asset
- - - - 0.07

Freeline Therapeutics Holdings Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.07 0.07 0.08 0.08

Competitive Comparison of Freeline Therapeutics Holdings's Debt-to-Asset

For the Biotechnology subindustry, Freeline Therapeutics Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Freeline Therapeutics Holdings's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's Debt-to-Asset falls into.



Freeline Therapeutics Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Freeline Therapeutics Holdings's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Freeline Therapeutics Holdings's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Freeline Therapeutics Holdings  (NAS:FRLN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Freeline Therapeutics Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.